Richard Oetheimer > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices

100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Richard Oetheimer

Position
Partner
Career
Rich Oetheimer, a partner in Goodwin’s Products Litigation and Counseling practice, specializes in the defense of mass tort and products liability actions, and business and real estate litigation.
Richard has extensive experience in the defense of product liability and mass tort claims against manufacturers of prescription drugs, medical devices, chemical substances, foods and dietary supplements, cosmetics and consumer products. His experience includes defense of asbestos, talc, DES, PPA, Reglan/metoclopramide, Pradaxa, ephedra, heart valve and Dalkon Shield IUD litigation, including participation in jury trials in federal and state courts. He served as lead counsel in the U.S. Supreme Court case that established federal preemption of generic drug failure to warn lawsuits and participated as amicus in the follow-on case finding federal preemption of generic drug design defect claims.
Richard also has extensive experience in business and financial services litigation, including defense of residential mortgage lenders in state and federal courts, and is active in all types of real estate and land use litigation, including many cases and multiple trials in Massachusetts’ specialized Land Court.
Education
JD, University of California, Berkeley School of Law 1981 / Boston College (summa cum laude) 1978
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation